Severe COVID: Study Finds Vaccines/Boosters not Associated

Severe COVIDThe Journal of American Medical Association (JAMA), (Kelley, JD, et al.) published “Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines” on October 11, 2022. Researchers investigated the incidence of severe COVID illness following vaccination/booster with BNT162b2, mRNA-1273, and Ad26.COV2.S in adults receiving care at Veterans Health Administration (VHA) facilities. This study took place at VHA facilities across the US between July 1, 2021, and May 30, 2022, when Delta and Omicron variants of COVID predominated. 

This study evaluated 1,610,719 patients of which 68.4% of the study population were 65 years or older; 8.2% were female; 70.4%; had high-risk comorbid conditions; 9.6% had immunocompromising conditions; and 91.1% received the same type/regime of mRNA vaccine series and booster. 

Results of the study showed that in this nationwide Veterans Health Administration patient population, there was a low incidence of hospitalization with COVID-associated pneumonia or death post vaccination/booster with any of the BNT162b2, mRNA-1273, or Ad26.COV2.S vaccines. 

For More Information 

Read Full Journal Article

Other LDA Articles that Relate